EGFR and colorectal carcinoma: The CRC PDOs knocked out of all RASGAPs were generated using CRISPR technology, only the NF1 deficiency led to improved tolerance to limited EGF stimulation and enhanced activation of RAS-ERK signaling, suggesting that the loss of NF1 in CRCs may not response to anti-EGFR therapy [87].